KIN-3248 is under clinical development by Kinnate Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KIN-3248’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData
Report-cover

Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - KIN-3248 in Solid Tumor

Buy the Report

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KIN-3248 overview

KIN-3248 is under development for the treatment of FGFR2-fusion positive intrahepatic cholangiocarcinoma (ICC) and FGFR3-altered urothelial carcinoma. The drug candidates acts by targeting FGFR2 and 3. It is administered through oral route.

Kinnate Biopharma overview

Kinnate Biopharma is a biotechnology company that develops the small molecule kinase inhibitor candidates for difficult-to-treat, cancers associated with genetic alterations. It advancing the development of its lead-targeted therapy FGFR and RAF candidates. The company also provide BRAF protein and biomarker-driven approach to drive the preclinical and clinical development of its translational research programs. Kinnate Biopharma also carries out small molecule development programs, such as Cyclin-Dependent Kinase 12 (CDK12) inhibitor in KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC). It has operations in San Francisco, the US. Kinnate Biopharma is headquartered in San Diego, California, the US.

For a complete picture of KIN-3248’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.